Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045617 · ClinicalTrials.gov registry record · Phase 2
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00045617 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 9 participants.
The verdict
NCT00045617, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who have limited-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG etoposide
- RADIATION radiation therapy
- BIOLOGICAL monoclonal antibody 11D10 anti-idiotype vaccine
- BIOLOGICAL monoclonal antibody GD2 anti-idiotype vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045617
The ClinicalTrials.gov registry entry for NCT00045617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00045617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045617 about?
NCT00045617 is a clinical study titled "S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation thera...
What is the current status of trial NCT00045617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2003-01. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00045617?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), monoclonal antibody 11D10 anti-idiotype vaccine (BIOLOGICAL), monoclonal antibody GD2 anti-idiotype vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045617?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.